$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-Q Financial Statement

#000162828018003346 Filed on March 19, 2018

Income Statement

Concept	2018 Q1	2017 Q1
Revenue	$5.082M	$3.565M
YoY Change	42.55%	39.69%
Cost Of Revenue	$2.473M	$2.410M
YoY Change	2.61%	14.22%
Gross Profit	$2.609M	$1.160M
YoY Change	124.91%	157.78%
Gross Profit Margin	51.34%	32.54%
Selling, General & Admin	$1.631M	$1.562M
YoY Change	4.42%	-14.18%
% of Gross Profit	62.51%	134.66%
Research & Development	$1.045M	$998.0K
YoY Change	4.71%	-0.1%
% of Gross Profit	40.05%	86.03%
Depreciation & Amortization	$98.00K	$34.00K
YoY Change	188.24%	9.68%
% of Gross Profit	3.76%	2.93%
Operating Expenses	$5.149M	$4.966M
YoY Change	3.69%	0.83%
Operating Profit	-$67.00K	-$1.401M
YoY Change	-95.22%	-40.96%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$7.000K	-$8.000K
YoY Change	-12.5%	0.0%
Pretax Income	-$74.00K	-$1.409M
YoY Change	-94.75%	-40.82%
Income Tax	$2.000K	$0.00
% Of Pretax Income
Net Earnings	-$76.00K	-$1.409M
YoY Change	-94.61%	-41.59%
Net Earnings / Revenue	-1.5%	-39.52%
Basic Earnings Per Share	-$0.01
Diluted Earnings Per Share	-$0.01	-$128.5K
COMMON SHARES
Basic Shares Outstanding	10.99M shares	10.97M shares
Diluted Shares Outstanding	10.99M shares

Balance Sheet

Concept	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.060M	$3.490M
YoY Change	-69.63%	6.08%
Cash & Equivalents	$1.100M	$3.488M
Short-Term Investments
Other Short-Term Assets	$190.0K	$540.0K
YoY Change	-64.81%	31.71%
Inventory
Prepaid Expenses
Receivables	$2.942M	$2.026M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$4.189M	$6.055M
YoY Change	-30.82%	4.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.980M	$672.0K
YoY Change	194.64%	31.76%
Goodwill	$669.0K	$669.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$107.0K	$150.0K
YoY Change	-28.67%	0.0%
Total Long-Term Assets	$2.906M	$1.491M
YoY Change	94.9%	11.27%
TOTAL ASSETS
Total Short-Term Assets	$4.189M	$6.055M
Total Long-Term Assets	$2.906M	$1.491M
Total Assets	$7.095M	$7.546M
YoY Change	-5.98%	5.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.961M	$1.324M
YoY Change	48.11%	-12.89%
Accrued Expenses	$365.0K	$327.0K
YoY Change	11.62%	25.77%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.00K
YoY Change
Total Short-Term Liabilities	$6.177M	$5.272M
YoY Change	17.17%	13.38%
LONG-TERM LIABILITIES
Long-Term Debt	$20.00K	$0.00
YoY Change
Other Long-Term Liabilities	$446.0K	$234.0K
YoY Change	90.6%	-2.09%
Total Long-Term Liabilities	$446.0K	$234.0K
YoY Change	90.6%	-2.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.177M	$5.272M
Total Long-Term Liabilities	$446.0K	$234.0K
Total Liabilities	$6.623M	$5.506M
YoY Change	20.29%	12.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.19M	-$66.93M
YoY Change	4.88%	11.74%
Common Stock	$71.92M	$70.22M
YoY Change	2.42%	10.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.252M	$1.252M
YoY Change	0.0%	0.0%
Treasury Stock Shares	269.7K shares	269.7K shares
Shareholders Equity	$472.0K	$2.040M
YoY Change
Total Liabilities & Shareholders Equity	$7.095M	$7.546M
YoY Change	-5.98%	5.61%

Cashflow Statement

Concept	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$76.00K	-$1.409M
YoY Change	-94.61%	-41.59%
Depreciation, Depletion And Amortization	$98.00K	$34.00K
YoY Change	188.24%	9.68%
Cash From Operating Activities	$440.0K	-$684.0K
YoY Change	-164.33%	-5.0%
INVESTING ACTIVITIES
Capital Expenditures	-$80.00K	-$150.0K
YoY Change	-46.67%	7.14%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$80.00K	-$150.0K
YoY Change	-46.67%	7.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	30.00K	-10.00K
YoY Change	-400.0%	0.0%
NET CHANGE
Cash From Operating Activities	440.0K	-$684.0K
Cash From Investing Activities	-80.00K	-150.0K
Cash From Financing Activities	30.00K	-10.00K
Net Change In Cash	390.0K	-$684.0K
YoY Change	-157.02%	-21.38%
FREE CASH FLOW
Cash From Operating Activities	$440.0K	-$684.0K
Capital Expenditures	-$80.00K	-$150.0K
Free Cash Flow	$520.0K	-$534.0K
YoY Change	-197.38%	-7.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	472000	USD
	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	871000	USD
	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	5965000	USD
CY2018Q1	csbr	Assetsin Progress Gross AssetsinProgressGross	50000	USD
CY2017Q1	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	320000	USD
	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	1167000	USD
CY2018Q1	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	220000	USD
CY2017Q1	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2086000	USD
CY2018Q1	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2253000	USD
	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	6866000	USD
CY2014Q4	csbr	Monthly Capital Lease Payment MonthlyCapitalLeasePayment	3000	USD
	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2017Q1	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	347000	USD
	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	1354000	USD
CY2018Q1	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	259000	USD
	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	1077000	USD
	csbr	Property Plantand Equipment Cost Capitalization Amount PropertyPlantandEquipmentCostCapitalizationAmount	100000	USD
	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted		USD
	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P5Y9M18D
	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	0	shares
	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
CY2018Q1	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	2004284	shares
	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0.00
	csbr	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit	7000000	USD
CY2017Q1	csbr	Translational Oncology Solutions TranslationalOncologySolutions	3218000	USD
	csbr	Translational Oncology Solutions TranslationalOncologySolutions	10337000	USD
CY2018Q1	csbr	Translational Oncology Solutions TranslationalOncologySolutions	4823000	USD
	csbr	Translational Oncology Solutions TranslationalOncologySolutions	14242000	USD
CY2018Q1	csbr	Working Capital Deficit WorkingCapitalDeficit	2000000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-01-31
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11000847	shares
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
	dei	Trading Symbol TradingSymbol	CSBR
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1852000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1961000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2274000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2942000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	685000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	365000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1122000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1359000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	70991000	USD
CY2018Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	71906000	USD
CY2017Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1900000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1901000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	152000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	863000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4418544	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4523129	shares
CY2017Q2	us-gaap	Assets Assets	8011000	USD
CY2018Q1	us-gaap	Assets Assets	7095000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	5869000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	4189000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	23000	USD
CY2017Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2018Q1	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	130000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	52000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	26000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	16000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	28000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	3000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	49000	USD
CY2018Q1	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	8000	USD
CY2018Q1	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.05
CY2017Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	872000	USD
CY2018Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	961000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2585000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3488000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3295000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1062000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1100000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	903000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2233000	USD
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11251844	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11277675	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10982159	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11000847	shares
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4910000	USD
CY2018Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3851000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	34000	USD
	us-gaap	Depreciation Depreciation	108000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	98000	USD
	us-gaap	Depreciation Depreciation	233000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	127000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	253000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.44
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.01
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.08
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	203420	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P4Y3M19D
CY2017Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	74000	USD
CY2018Q1	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	73000	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	836000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3393000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1004000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3167000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2018Q1	us-gaap	Goodwill Goodwill	669000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1409000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4453000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-826000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	18000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-572000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	124000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	714000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	669000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	55000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-320000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	483000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1059000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	20000	USD
	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	302000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	98000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-115000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	20000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	15000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	297000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	480000	USD
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2018Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	0	USD
CY2017Q2	us-gaap	Liabilities Liabilities	7611000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	6623000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8011000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7095000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7447000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6177000	USD
CY2017Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1500000.0	USD
CY2017Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	918000	USD
CY2018Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2255000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4322000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1017000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3238000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1235000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1200000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1408904	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1409000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4459773	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4460000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-76000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-844000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-33000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-7000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-71000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	4966000	USD
	us-gaap	Operating Expenses OperatingExpenses	16111000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	5149000	USD
	us-gaap	Operating Expenses OperatingExpenses	16074000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1401000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4420000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-67000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-755000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	107000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	107000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	164000	USD
CY2018Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	446000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-8000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-33000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-71000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	742000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	181000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1017000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	185000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4340000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	38000	USD
	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	910000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2338000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3339000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1216000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3217000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	19000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1980000	USD
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	18000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	998000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69350000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70193000	USD
CY2017Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3565000	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	11691000	USD
CY2018Q1	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	5082000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1045000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3308000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	15319000	USD
CY2017Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	726000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2369000	USD
CY2018Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	627000	USD
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1862000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1901000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	848000	USD
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8559
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8796
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8796
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8766
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7212
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7212
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8559
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0198
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0190
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0198
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0059
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0059
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0177
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2415307	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.77
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	38627	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	6042	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	267310	shares
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.35
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.71
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.32
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.95
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1282000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3921000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2308704	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2518845	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.86
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.80
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	3921000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2518845	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	56529	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.21
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.58
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.68
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P3Y
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	3847000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y9M18D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	12500	shares
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	15000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	400000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	472000	USD
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2018Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2018Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	121000	USD
CY2018Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	121000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10967738	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10130460	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10994434	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10987797	shares
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10967738	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10130460	shares
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10994434	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10987797	shares

Files In Submission

Name	View Source	Status
0001628280-18-003346-index-headers.html	Edgar Link	pending
0001628280-18-003346-index.html	Edgar Link	pending
0001628280-18-003346.txt	Edgar Link	pending
0001628280-18-003346-xbrl.zip	Edgar Link	pending
csbr-20180131.xml	Edgar Link	completed
csbr-20180131.xsd	Edgar Link	pending
csbr-20180131_cal.xml	Edgar Link	unprocessable
csbr-20180131_def.xml	Edgar Link	unprocessable
csbr-20180131_lab.xml	Edgar Link	unprocessable
csbr-20180131_pre.xml	Edgar Link	unprocessable
csbr10-q1312018.htm	Edgar Link	pending
csbrq2131201810-qex311.htm	Edgar Link	pending
csbrq2131201810-qex312.htm	Edgar Link	pending
csbrq2131201810-qex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2018 Q1 Form 10-Q Financial Statement

#000162828018003346 Filed on March 19, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2018 Q1 Form 10-Q Financial Statement

#000162828018003346 Filed on March 19, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr